Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ionis, AstraZeneca To Use Real-World Data To Accelerate RNA-Targeting Cholesterol Drug

Phase I Shows Promise, But ION449 Must Catch Up With Inclisiran

Executive Summary

Early data presented at the American Heart Association showed strong PCSK9 and LDL cholesterol lowering for ION449; AstraZeneca plans rapid development under an RWE-based FDA pilot program.

You may also be interested in...



AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate

AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.

Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval

Timing means full EU approval could coincide with US FDA authorization later this year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel